Improving treatment for blood cancers in children
Official title: COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children
Funded at Public Health Institute · NIH-10791885 · Data updated 2026-11-12
This study is looking for better and safer treatments for kids with blood cancers like leukemia and lymphoma, aiming to find specific targets that can help improve their chances of survival and quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Public Health Institute NIH-funded |
| Lab location | 1 site (Oakland, United States) |
| Project start | March 1, 2022 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $427,843 |
| NIH project number | 5UG1CA233249-06 |
| Project ID | NIH-10791885 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children diagnosed with hematopoietic malignancies such as leukemia or lymphoma.
✕Less likely to help
Patients with non-hematopoietic cancers or those who are not children may not receive benefit from this research.
What this research studies
This research focuses on understanding hematopoietic malignancies, such as leukemias and lymphomas, which are significant causes of cancer in children. The project aims to identify specific biological targets that can lead to more effective and less harmful treatments, reducing the reliance on traditional cytotoxic therapies. By leveraging data from previous studies, the research seeks to enhance risk stratification and develop targeted therapies that improve survival rates and quality of life for young cancer patients. The Children’s Oncology Group collaborates with the National Cancer Institute to advance these efforts.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for children with blood cancers.
How similar studies have gone: Previous studies have shown success in identifying targeted therapies for other cancers, indicating potential for similar advancements in hematopoietic malignancies.
Where this research is happening
-
Public Health Institute
Oakland, United States Active
Researchers
- Principal investigator: Meshinchi, Soheil — Public Health Institute
- Study coordinator: Meshinchi, Soheil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.